ASH 2025

#ASH25 #mmsm @ASH_hematology Treatment Refinement in Multiple Myeloma @SLentzsch Reasons why CAR-T should be positioned before BsAbs

🧵 All #ASH25 abstracts for #mmsm in a tweet 10+ Bonus: 1/10: Presentation ID 2387  OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study #mmsm #Myeloma #USMIRC #MedEd #MedTwitter @USMIRCNEWS

Bonus from #ASH25 late abstract: 🧵1/🚨 Breaking from #ASH25! LBA-1 unveils early results from inMMyCAR, the first-in-human Phase 1 study of KLN-1010, a novel in vivo anti-BCMA CAR-T gene therapy for RRMM. #MultipleMyeloma #CellTherapy #mmsm #myeloma #MedEd #MedTwitter #USMIRC

#ASHkudos to @SLentzsch This is the nicest and most succinct explanation I’ve seen for CAR-T before bsAbs in myeloma 👏 And I agree! Even once MajesTEC-3 approved based on #ASH25 results, please make sure #MMsm pts hear about BCMA CAR-T as an option before starting bsAbs!

Every BCMA CAR-T company has eyes on this talk 👀. The arrival of in vivo CAR-T is an iPhone-moment — and we know how that ended for Nokia and Blackberry. 📉📈 #ASH25 @oncodaily #MedEd #MedTwitter #mmsm @DrPaulyDeSantis @RenoHemonc

1/10 ASH Abstract #ASH2025 #ASHmmsm OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study from 🇨🇳 1/New bispecific CAR-T for multiple myeloma! OL-101 targets both BCMA & GPRC5D using VHH binders to

Just in time for #ASH25 MRD in Myeloma: all your questions answered! How to use MRD assessment in practice and research. @ZanwarSaurabh @LeukemiaJnl For a limited time get free access through this link: The principles we discuss apply for all

Many congratulations to the GCLLSG for the first read out of #CLL17 No PFS diff between I+V vs I vs VO. Shorter fup but v different to FLAIR results showing a marked PFS adv for MRD-directed I+V vs I. #ASH25

While single-arm, the 100% MRD-negativity at 10^-6 with short course of Linvosiltemab post-induction is striking! Awaiting the FASTER RCT [Elra vs ASCT] from @CoMMitTrials but hard to imagine Mel-200 will achieve such high MRD-conversion rate based on prior data! #ASH25

#ASH25 #leusm #ALL #ASHKudo Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo •Higher CHR + MRD responses, fewer deaths, better EFS/OS •More MRD negativity + fewer relapses vs prior trial •Crossover helps rescue MRD+ patients •Biology-driven

#2 Dual targeting BCMA and CD19 Fastcar-t (GC012F/AZD0120) as first-line therapy for myeloma. Juan Du et al. Novel, next day manufacturing of CART cells! Highly effective 81% sustained (12 month) MRD negative rate. Also dual targeted. #ASH25 Link:

#ASH25 @Anand_88_Patel present data on InO plus dasatinib for Ph+ #ALL 👏👏 Summary: High ≥MR3 rates after 2 cycles of dasatinib + InO VOD seen only in Schema 1; none in Schema 2 Switching to ponatinib boosts depth of response 100% achieved MR4 or NGS-MRD– by Course 3 76% EFS

Teclistamab doses can be reduced by half, given for a limited time, and remain highly effective for RR MM patients maximizing access. Look for the TECLISito poster on Sunday at #ASH25 #Shouldvebeenoral #MMsm @rennquevedo @dgomezalmaguer

Presented at #ASH25: In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common. Full RedirecTT-1 phase 1b–2 study

Finally I found the 10th abstract for #ASH25 🔥🔥🔥 Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of DPd/DVd in Pts with RRMM: majestec-3 1/ 🔥 Practice-changing data in RRMM! MajesTEC-3 is the first phase 3 trial of a BCMA×CD3 bispecific

Original Article: Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab (RedirecTT-1 phase 1b–2 study) #ASH25 | @ASH_hematology

Just out in @NEJM Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 #ASH25 @myelomaMD @szusmani @mvmateos 80% response rate. 60% PFS at 12 months.

1/10 ASH Abstract #ASH2025 #ASHmmsm OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study from 🇨🇳 1/New bispecific CAR-T for multiple myeloma! OL-101 targets both BCMA & GPRC5D using VHH binders to

Abstract 9/10 #ASH25; From the world 🌍 1/🚨 Abstract #abs25-7875 🔥 Updated efficacy & safety data for JNJ-5322, a next-gen BCMA × GPRC5D × CD3 trispecific antibody for relapsed/refractory multiple myeloma (RRMM)! #ASH25 #Myeloma #Immunotherapy #mmsm #myeloma #MedEd

#ASH25 Key abstracts to watch in MDS/CMML 👇 ➡️ Deeper insights into Ven+Aza across high-risk and therapy-related #MDS ➡️ Momentum in telomerase inhibitors, TPO agonists & precision-fusion agents ➡️ Emerging immunotherapy strategy for #TP53 mutant disease ➡️ Fascinating

#ASH25 👇Key abstracts to watch in acute lymphoblastic leukemia #ALL #leusm 🧵 Overall Takeaways — ASH 2025 ALL Landscape Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL. TKI + immunotherapy (blina / InO) emerging as new standard-contenders.

I'm writing for @ASH_hematology #ASHNewsDaily this year! Check out my article previewing #ASH25 Education Program sessions about immunotherapies invading earlier lines of therapy, including interviews with Drs. Doris Hansen, @NicBoissel & @drsarahruth.

#ASH25 #leusm #ALL #ASHKudo Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo •Higher CHR + MRD responses, fewer deaths, better EFS/OS •More MRD negativity + fewer relapses vs prior trial •Crossover helps rescue MRD+ patients •Biology-driven

#ASH25 nice work by the US #MMsm Immunotherapy Consortium: CRS doesn’t intrinsically increase the risk of cardiac events after teclistamab bsAb therapy, but prior cardiac history does - co-management with a cardiologist is imperative!

SMART STOP primary analysis @Lymphoma_Doc #ASH25 - 61 pts, 56% high IPI, 61% non-GC - at end of all tx, CR 97% - 57% avoided 6 cycles R-CHOP - 24-mo PFS/OS 85%/98% for whole cohort Looking forward to ctDNA data! #lymsm

Longitudinal PhasEDSeq ctDNA after 1L tx #ASH25 - >150 pts - on tx clearance rates: 28% C2D1, 64% C4D1, 81% EOT - increasing prognostic value over time - 91% w/ confirmed relapse were MRD+ at EOT or during f/u - if no PD: 96% neg EOT MRD Now we just want the assay! #lymsm

WGS of cfDNA for assessment of MRD [MRDetect] in HR-SMM [Nov 3, 2025] Baker et al. @BenDiamondMD #ASH25 abs25-4528 PID 3920 #NCT01572480 #mmsm #mmMRD #cagenome #LiquidBiopsy

WGS of cfDNA for assessment of MRD [MRDetect] in HR-SMM [Nov 3, 2025] Baker et al. @BenDiamondMD #ASH25 abs25-4528 PID 3920 #NCT01572480 #mmsm #mmMRD #cagenome #LiquidBiopsy

ctDNA data. 69% MRD neg at time of CR. Do we really need 17 cycles if MRD neg? #ASH25 #lymsm

1/#ASH25 Myeloproliferative syndromes and neoplasms: beyond JAK inhibitors Mutant calreticulin-targeting: INCA033989   @Dr_Vikas_Gupta Dr. John Mascarenhas @TischCancer ADC TCEs

#ASH25 Pivekimab (anti-CD123 ADC) plus Venetoclax/Azacitidine. Presented by Dr. Naval Daver #AML #leusm

Race agnostic models maintain accuracy in predicting M-protein levels in multiple myeloma [Nov 3, 2025] @rahul2u et al. #ASH25 abs25-11347 PID 2810 #mmsm #AI #CancerDisparities